Free beta access. 5 free AI tokens each week. Optional top-ups available. See what is included
Opening Word document…

Chinese firms lack incentive to innovate and are stifled by uncertain regulation and business environment

Li et al. 21 (Daitian Li, Assistant Professor at the University of Electronic Science & Technology of China, Harvard Business Review, “Is China Emerging as the Global Leader in AI”, February 18, 2021)//SW

By many indicators, China is now on the global frontier of AI in terms of technological development and market applications. The unique technological, market, policy environments that Chinese firms face in the emerging AI sector have given them a window of opportunity to catch up with global leaders rapidly.

But, paradoxically, while China may have caught up in record time, the conditions that have allowed it to do so may impede its further development in AI.

For example, given the open science nature of AI and the advantages of being quick followers, Chinese firms often lack strong incentives to invest in developing core AI technologies. Unlike in Western developed economies where companies are the primary holders of AI patents, in China, the majority of AI patents are filed by universities and research institutes, most of which are government owned or sponsored. However, university-industry linkages in China are relatively weak, and technology transfer remains rather limited. Overall, although aggregate AI research outputs (e.g., scientific publications, patents) are rising rapidly in China, truly original ideas and breakthrough technologies are lacking.

Further, the uncertain business environment in China, coupled with the huge market for AI products and Chinese consumers’ enthusiasm to adopt them, leads companies and investors to favor applied AI research that can bring quick money instead of more basic research that promises to have long-lasting impacts. At a more fundamental level, the research culture in China needs a great deal of improvement, .

On the policy front, the relaxed regulatory environment has proved to be a double-edged sword. While some firms are bold enough to take advantage of such environment by aggressively pushing different AI applications to markets, others feel frustrated as they don’t know what is allowed due to such policy uncertainty. The chairman of Suzhou Blue Amber Medi-Tech, a medical device company, lamented that this uncertainty has led his company to decide to not touch any data that might fall into certain gray areas (e.g., use of personal health data for other commercial purposes). “Our current thinking is that if we don’t need to touch the data, we will not touch it. … But, if we do not touch the data, a significant part of the value [of the data] is not realized. So, from our company’s point of view, we do hope that the government will make the regulations clear sooner.”

Sign in to recut, update, or save this card.